Навчальний курс: «Молекулярна онкологія, патологія та генетика» Медична лабораторія CSD спільно з Center for research and education of translational biology and medicine (www.tbm.center ) пропонує безкоштовний курс навчальних лекцій для усіх бажаючих.

1. MOLECULAR DIAGNOSTICS IN BREAST
CANCER MANAGEMENT
Oksana Sulaieva

2. CONVENTIONAL DECISION-MAKING APPROACH
IN BREAST CANCER
Clinical
diagnosis
Prognosis
Tailored
treatment

3. Yuan J et al. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 2018 Oct 8;34(4):549-560.e9. doi: 10.1016/j.ccell.2018.08.019.
WHY DO WE NEED MOLECULAR TESTING in BREAST CANCER?

4. Reason # 1

5. Major cancer susceptibility
loci identified in breast
cancer.
WHY DO WE NEED MOLECULAR TESTING in BREAST CANCER?
Santarpia L. et al. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist. 2016 Sep;21(9):1063-78. doi: 10.1634/theoncologist.2015-0369.

6. What genes should be tested?
CLINICAL IMPLICATIONS
• risk assessment
• prognosis
• targeted treatment
NGS TESTING SHOULD BE PREFERRED FOR assessing BRCA1/2 and other HRR-genes

7. Reason # 2

8. MOLECULAR TOOLS FOR BREAST CANCER
(LUMINAL SUBTYPES, EARLY STAGES)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 7.2021 – August 23, 2021

9. 10
Oncotype DX Breast

11. Reason # 3

12. WHY DO WE NEED MOLECULAR TESTING in BREAST CANCER?
List of recurrent drivers in breast cancer
Condorelli R et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.

13. LIST OF GENOMIC ALTERATIONS OF LOE I/II
Condorelli R et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.

15. Tailoring
treatment for the
best patients’
benefits
NGS-panels (Illumina platform)
Complex genomic profiling – Foundation One Dx
All the types of genetic alterations
Complex genomic signatures
SHIFTING HEALTH CARE PARADIGM TOWARDS PRECISE MEDICINE

16. Reason # 4

17. Tools for molecular residual disease detection and
optimizing patients' management

18. MOLECULAR TESTING APPLICATIONS:
• Hereditary cancer diagnostics and family risks assessment
• Identifying patients with high risk of recurrence and making a
decision on the best treatment options (Luminal Types)
• Evaluating predictive markers for tailoring treatment for the best
patients benefits
• Non-invasive cancer monitoring and molecular residual disease
detection
• Comprehensive genomic profiling supports clinicians in decision
making and improves patients` outcomes and care
NGS-panels for solid
tumors
NGS-panel for BRCA1/2 testing
30-genes panel for hereditary cancer
CONCLUSIONS

19. THANK YOU FOR ATTENTION!